Zoledronic acid: multiplicity of use across the cancer continuum

References

• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer2(8), 584–593 (2002).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer80(8 Suppl.), 1588–1594 (1997).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer16(8), 879–889 (2008).
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer113(6), 1438–1445 (2008).
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol.16(4), 579–584 (2005).
   PubMed Web of Science ®Google Scholar
• Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev.34(2), 183–192 (2008).
   PubMed Web of Science ®Google Scholar
• Lipton A. Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res. Treat.122(3), 627–636 (2010).
   PubMedGoogle Scholar
• Lattouf JB, Saad F. Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr. Opin. Urol.20(3), 247–252 (2010).
   PubMedGoogle Scholar
• Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol.14(5), 1718–1729 (1996).
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol.19(14), 3306–3311 (2001).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer98(8), 1735–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet376(9757), 1989–1999 (2010).
   PubMed Web of Science ®Google Scholar
• Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist10(1), 52–62 (2005).
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Dunn JA, Kanis JA, MacLennan ICM, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br. J. Haematol.113(4), 1035–1043 (2001).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96(11), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol.23(15), 3314–3321 (2005).
   PubMed Web of Science ®Google Scholar
• Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer88(5), 1082–1090 (2000).
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol.14(9), 1399–1405 (2003).
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer90(6), 1133–1137 (2004).
   PubMed Web of Science ®Google Scholar
• Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol.11(1), 59–65 (1993).
   PubMed Web of Science ®Google Scholar
• Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull. Cancer88(7), 701–707 (2001).
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med.246(1), 67–74 (1999).
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol.28, 5132–5139 (2010).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer100(1), 36–43 (2004).
   PubMed Web of Science ®Google Scholar
• Henry D, von Moos R, Vadhan-Raj S et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at: The Joint ECCO 15–34th ESMO Multidisciplinary Congress. Berlin, Germany, 20–24 September 2009 (Abstract 20LBA).
   Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev.3, CD003474 (2005).
   Google Scholar
• Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet377(9768), 813–822 (2011).
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev.19(1), 80–100 (1998).
   PubMed Web of Science ®Google Scholar
• Juillard A, Falgayrac G, Cortet B et al. Molecular interactions between zoledronic acid and bone: an in vitro Raman microspectroscopic study. Bone47(5), 895–904 (2010).
   PubMedGoogle Scholar
• Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol.42(11), 1228–1236 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol.21(16), 3150–3157 (2003).
   PubMed Web of Science ®Google Scholar
• Zometa (zoledronic acid) injection [package insert]. Novartis Pharmaceuticals Corporation, NJ, USA (2008).
   Google Scholar
• Skerjanec A, Berenson J, Hsu C et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol.43(2), 154–162 (2003).
   PubMed Web of Science ®Google Scholar
• Dunford JE, Kwaasi AA, Rogers MJ et al. Structure–activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem.51(7), 2187–2195 (2008).
   PubMed Web of Science ®Google Scholar
• Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone. Miner. Res.13(4), 581–589 (1998).
   PubMed Web of Science ®Google Scholar
• Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J. Bone. Miner. Res.9(5), 745–751 (1994).
   PubMed Web of Science ®Google Scholar
• Raikkonen J, Monkkonen H, Auriola S, Monkkonen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem. Pharmacol.79(5), 777–783 (2010).
   PubMed Web of Science ®Google Scholar
• Monkkonen H, Auriola S, Lehenkari P et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol.147(4), 437–445 (2006).
   PubMed Web of Science ®Google Scholar
• Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains suppression of osteolysis in patients with malignant bone disease. Presented at: The International Bone and Mineral Society Davos Workshops: Bone Biology and Therapeutics. Davos, Switzerland, 9–14 March 2008 (Abstract 199).
   Google Scholar
• Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol.19(2), 558–567 (2001).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J.7(5), 377–387 (2001).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer100(12), 2613–2621 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer113(1), 193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsh V, Major PP, Lipton A et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J. Thorac. Oncol.3(3), 228–236 (2008).
   PubMed Web of Science ®Google Scholar
• Body J-J, Cook R, Costa L et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Presented at: The IX International Meeting on Cancer Induced Bone Disease. Arlington, VA, USA, 28–31 October 2009 (Abstract 71).
   Google Scholar
• Xgeva (denosumab) injection [package insert]. Amgen Inc., CA, USA (2010).
   Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol.9(9), 840–849 (2008).
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Bosserman LD, Caradonna RR et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer9(2), 77–85 (2009).
   PubMed Web of Science ®Google Scholar
• de Boer R, Bundred N, Eidtmann H et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Presented at: The 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–12 December 2010 (Poster P5-11-01).
   Google Scholar
• Llombart A, Frassoldati A, Paija O et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Presented at: The American Society of Clinical Oncology 2009 Breast Cancer Symposium. San Francisco, CA, USA, 8–10 October 2009 (Abstract 213).
   Google Scholar
• Brufsky A, Harker WG, Beck JT et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 4083).
   Google Scholar
• Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol.26(29), 4739–4745 (2008).
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur. J. Cancer47(5), 683–689 (2011).
   PubMed Web of Science ®Google Scholar
• Hershman DL, McMahon DJ, Crew KD et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J. Clin. Endocrinol. Metab.95(2), 559–566 (2010).
   PubMedGoogle Scholar
• Singh S, Cuzick J, Edwards R et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Breast Cancer Res. Treat.106(Suppl. 1), S9 (2007) (Abstract 28).
   Google Scholar
• Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J. Clin. Oncol.28, 967–975 (2010).
   PubMed Web of Science ®Google Scholar
• Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res.14(19), 6336–6342 (2008).
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol.26(30), 4875–4882 (2008).
   PubMed Web of Science ®Google Scholar
• Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res.12(6), 214 (2010).
   PubMed Web of Science ®Google Scholar
• Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res.60(11), 2949–2954 (2000).
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br. J. Cancer88(10), 1631–1640 (2003).
   PubMed Web of Science ®Google Scholar
• Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res.15(11), 2211–2221 (2000).
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer84(8), 1126–1134 (2001).
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Deux B, Monkkonen H et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin. Cancer Res.14(14), 4658–4666 (2008).
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol. Cancer Ther.8(10), 2821–2832 (2009).
   PubMedGoogle Scholar
• Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, Phase 2 trial. Lancet Oncol.11(5), 421–428 (2010).
   PubMed Web of Science ®Google Scholar
• Greenberg S, Park JW, Melisko ME et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results. Presented at: The 46th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 4–8 June 2010 (Abstract 1002).
   Google Scholar
• Rack B, Juckstock J, Genss EM et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res.30(5), 1807–1813 (2010).
   PubMed Web of Science ®Google Scholar
• Solomayer EF, Gebauer G, Hirnle P et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res.69(Suppl. 2), 170S–171S (2009) (Abstract 2048).
   Web of Science ®Google Scholar
• Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med.353(8), 793–802 (2005).
   PubMed Web of Science ®Google Scholar
• Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol.19(12), 2007–2011 (2008).
   PubMed Web of Science ®Google Scholar
• Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res.8(2), R13 (2006).
   PubMed Web of Science ®Google Scholar
• Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol.43(7), 650–656 (2004).
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol.12(7), 631–641 (2011).
   PubMed Web of Science ®Google Scholar
• Coleman RE, Thorpe HC, Cameron D et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at: The 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–12 December 2010 (Abstract S4–S5).
   Google Scholar
• Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360(7), 679–691 (2009).
   PubMed Web of Science ®Google Scholar
• Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann. Oncol.21(11), 2188–2194 (2010).
   PubMed Web of Science ®Google Scholar
• Coleman R, Bundred NJ, de Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 4082).
   Google Scholar
• Coleman RE, Winter MC, Cameron D et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer102, 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Lipton A, Chapman JW, Demers L et al. Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer. Presented at: Primary Therapy of Early Breast Cancer 11th International Conference. St. Gallen, Switzerland, 11–14 March 2009 (Abstract 244).
   Google Scholar
• Lipton A, Chapman JW, Demers L et al. Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer: NCIC CTG MA.14. J. Clin. Oncol. (2011) (In Press).
   Google Scholar
• Coleman R, Burkinshaw R, Winter M et al. Zoledronic acid. Expert Opin. Drug Saf.10(1), 133–145 (2010).
   PubMedGoogle Scholar
• Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J. Clin. Endocrinol. Metab.95(9), 4380–4387 (2010).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J.7(5), 377–387 (2001).
   PubMed Web of Science ®Google Scholar
• Weitzman R, Sauter N, Eriksen EF et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients – May 2006. Crit. Rev. Oncol. Hematol.62(2), 148–152 (2007).
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.22(10), 1479–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J. Clin. Oncol.24(6), 945–952 (2006).
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone. Miner. Res.23(6), 826–836 (2008).
   PubMed Web of Science ®Google Scholar
• McArthur HL, Estilo C, Huryn J et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan–Kettering Cancer Center (MSKCC). J. Clin. Oncol.26(Suppl.), 523S (2008) (Abstract 9588).
   PubMed Web of Science ®Google Scholar
• Fehm T, Beck V, Banys M et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol. Oncol.112(3), 605–609 (2009).
   PubMedGoogle Scholar
• Fusco V, Loidoris A, Colella G, Vescovi P, Campisi G. Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. Breast19(5), 432–433; author reply 433–434 (2010).
   PubMedGoogle Scholar
• Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist13(3), 330–336 (2008).
   PubMed Web of Science ®Google Scholar
• Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol.27(32), 5356–5362 (2009).
   PubMed Web of Science ®Google Scholar
• Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral. Oncol.44(9), 857–869 (2008).
   PubMed Web of Science ®Google Scholar
• Badros A, Terpos E, Katodritou E et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol.26(36), 5904–5909 (2008).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol.20(1), 117–120 (2009).
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol.20(1), 137–145 (2009).
   PubMed Web of Science ®Google Scholar